CRISPR Therapeutics AG (CRSP) Non Operating Income (2015 - 2026)

CRISPR Therapeutics AG has reported Non Operating Income for 12 years, with the latest figure at $8.2 million in Q1 2026.

• Quarterly Non Operating Income fell 39.75% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.2 million (down 12.39% YoY) and the FY2025 annual result came in at $86.6 million, down 16.65% from the prior year.
• Non Operating Income slipped to $8.2 million in Q1 2026 per CRSP's latest filing, from $24.8 million in the prior quarter.
• Over five years, Non Operating Income peaked at $28.0 million in Q4 2024 and troughed at $363000.0 in Q1 2022.
• A 5-year average of $17.2 million and a median of $20.0 million in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income sank 81.43% in 2022, then surged 3410.19% in 2023.
• Over 5 years, Non Operating Income stood at $11.5 million in 2022, then surged by 74.04% to $20.0 million in 2023, then soared by 39.91% to $28.0 million in 2024, then slipped by 11.48% to $24.8 million in 2025, then plunged by 67.07% to $8.2 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $8.2 million, $24.8 million, and $26.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.